Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:KMPHNASDAQ:OGINASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$1.44+3.6%$1.41$1.03▼$2.57$287.71M1.221.52 million shs1.26 million shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsOGIOrganigram$1.28+8.5%$1.06$0.85▼$2.11$171.31M1.35693,058 shs1.58 million shsVERAVera Therapeutics$22.49+3.6%$24.07$18.53▼$51.61$1.43B1.28775,189 shs632,275 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences+3.60%-2.04%+11.63%-35.43%-23.81%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%OGIOrganigram+8.47%+15.32%+24.27%-11.11%-27.27%VERAVera Therapeutics+3.31%-11.91%+0.27%-33.93%-45.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.8455 of 5 stars3.51.00.00.02.73.31.3KMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram0.4032 of 5 stars0.03.00.00.01.00.01.3VERAVera Therapeutics3.4239 of 5 stars4.63.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.00Buy$10.50629.17% UpsideKMPHZevra Therapeutics 0.00N/AN/AN/AOGIOrganigram 3.00BuyN/AN/AVERAVera Therapeutics 3.10Buy$63.33181.61% UpsideCurrent Analyst Ratings BreakdownLatest OGI, KMPH, ATAI, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.003/19/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.002/27/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $61.002/13/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$308K934.11N/AN/A$1.47 per share0.98KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00OGIOrganigram$166.12M1.03N/AN/A$1.83 per share0.70VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%5/13/2025 (Estimated)KMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/AOGIOrganigram-$33.39M-$0.38N/AN/AN/A-31.69%-8.59%-6.54%N/AVERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%N/ALatest OGI, KMPH, ATAI, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025ATAIAtai Life Sciences-$0.19N/AN/AN/AN/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81KMPHZevra Therapeutics0.1410.1010.10OGIOrganigramN/A3.361.85VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%KMPHZevra Therapeutics19.39%OGIOrganigram34.63%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%KMPHZevra Therapeutics1.10%OGIOrganigram0.09%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80199.80 million115.45 millionOptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableOGIOrganigram860133.84 million126.10 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableOGI, KMPH, ATAI, and VERA HeadlinesRecent News About These CompaniesVera Therapeutics price target lowered to $55 from $60 at ScotiabankMay 12 at 6:57 PM | msn.comVera Therapeutics (NASDAQ:VERA) Releases Earnings Results, Misses Estimates By $0.06 EPSMay 12 at 2:33 PM | marketbeat.comAlgert Global LLC Acquires 15,386 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 12 at 4:15 AM | marketbeat.comHC Wainwright Issues Pessimistic Estimate for VERA EarningsMay 11 at 8:12 AM | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Raised by WedbushMay 11 at 8:12 AM | marketbeat.comHC Wainwright Forecasts Lower Earnings for Vera TherapeuticsMay 11 at 1:11 AM | americanbankingnews.comEvercore ISI Remains a Buy on Vera Therapeutics (VERA)May 10 at 8:02 PM | theglobeandmail.comWhat is Wedbush's Estimate for VERA Q1 Earnings?May 10 at 9:12 AM | marketbeat.comQ2 Earnings Forecast for VERA Issued By HC WainwrightMay 10 at 7:21 AM | marketbeat.comBalyasny Asset Management L.P. Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 10 at 5:20 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by The Manufacturers Life Insurance CompanyMay 10 at 4:11 AM | marketbeat.comBrokers Offer Predictions for VERA Q2 EarningsMay 10 at 3:07 AM | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Price Target Cut to $100.00 by Analysts at Cantor FitzgeraldMay 10 at 2:19 AM | americanbankingnews.comQ2 Earnings Forecast for Vera Therapeutics Issued By WedbushMay 10 at 1:21 AM | americanbankingnews.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comQ1 Earnings Estimate for VERA Issued By HC WainwrightMay 9, 2025 | marketbeat.comCrestline Management LP Acquires 79,032 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 8, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Position Raised by Cutter Capital Management LPMay 8, 2025 | marketbeat.comHC Wainwright Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)May 7, 2025 | marketbeat.comVera Therapeutics shares fall as Q1 loss exceeds estimatesMay 6, 2025 | investing.comVera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Stocks Have Huge Last 12 Months Shareholder YieldsBy Leo Miller | April 18, 2025View These 3 Stocks Have Huge Last 12 Months Shareholder Yields3 Tech Leaders Announce Buybacks Totaling $85 BillionBy Leo Miller | May 5, 2025View 3 Tech Leaders Announce Buybacks Totaling $85 Billion3 High-Value Companies With Triple-Digit Upside PotentialBy Nathan Reiff | April 16, 2025View 3 High-Value Companies With Triple-Digit Upside PotentialWhy Uber’s Stock Could Soar on AV Growth and Tariff ResilienceBy Jea Yu | April 16, 2025View Why Uber’s Stock Could Soar on AV Growth and Tariff ResilienceThe Top 3 Stock Picks at the World’s Greatest Hedge FundBy Leo Miller | May 2, 2025View The Top 3 Stock Picks at the World’s Greatest Hedge FundOGI, KMPH, ATAI, and VERA Company DescriptionsAtai Life Sciences NASDAQ:ATAI$1.44 +0.05 (+3.60%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 05/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Zevra Therapeutics NASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Organigram NASDAQ:OGI$1.28 +0.10 (+8.47%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 05/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Vera Therapeutics NASDAQ:VERA$22.49 +0.78 (+3.59%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$21.41 -1.08 (-4.80%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
